ClinicalTrials.gg
CompletedNCT02271854Updated Apr 5, 2016Results posted

A Within-subject Study to Evaluate the Efficacy and Safety of Diclofenac Sodium Topical Gel 1% Compared to Placebo in Subjects Experiencing Delayed Onset Muscle Soreness

A Phase 3 interventional study of Diclofenac sodium gel 1% and Placebo in Muscle Soreness, sponsored by Novartis. Completed at 1 site in United States. Open to participants aged 18 Years to 35 Years. Per ClinicalTrials.gov, last updated 2016-04-05.

Sponsored by Novartis · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
102
Allocation
Randomized
Ages
18 Years to 35 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 86 studies in Myalgia with a site in United States — 13 open to participants now, 15 under way, none of them phase 3. Myalgia · United States.

Enrollment
16th of 77
102 · median 40
Started
2014
with 3 others
Phase 3
8 of 86
none open now
Registered
27th of 86
by date

Among the 86 studies in Myalgia with a site in United States, this one is the 16th largest by enrollment of the 77 interventional ones that give a count, is one of 4 that started in 2014, is one of 8 in phase 3, and was the 27th registered.

Myalgia

256 studies on the registry are indexed under Myalgia; 46 are open to participants now.

Browse Myalgia studies →

Open to participants now

13 of the 86 studies in Myalgia with a site in United States are open now. Recruiting first, the newest first:

8 more — sign in →

All 13 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 27 Myalgia studies recruiting now, 6 (22%) set no upper age limit and 20 (74%) stop at 75 or younger; 4 take children under 18; 17 take healthy volunteers.

This study: 18 Years to 35 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 86 studies in Myalgia with a site in United States, or all of them as a file.
02

Study summary

This study will assess the analgesic efficacy of DSG 1% compared to placebo in the reduction of the pain associated with DOMS

03

Conditions studied

  • Muscle Soreness

Browse trials for

04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects aged 18-35 years
  • Not engaged in regular lower extremity fitness activities in the past 6 months prior to screening
  • Willing to refrain from use of ice, heat and massage during the study
  • DOMS score ≥4 Pain at Rest (PAR) and a DOMS score ≥5 Pain on Walking (POW), with moderate or severe on categorical scale

Exclusion criteria

Exclusion Criteria:

  • Pain medication \& prior to randomization
  • Topical analgesic or anti-inflammatory treatment over the previous month
  • of >32 kg/m2

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
102 participants (actual)

Study arms

  • Experimental
    diclofenac sodium gel 1%

    diclofenac sodium gel 1% applied four times daily

    Drug: Diclofenac sodium gel 1% · Drug: Placebo

  • Placebo comparator
    Placebo

    Placebo gel applied four times daily

    Drug: Diclofenac sodium gel 1% · Drug: Placebo

Interventions

  • Diclofenac sodium gel 1% four times daily (This study is a within-subject design i.e. active drug applied to one leg and placebo to the other leg at the same time. Therefore the study design is not a cross-over).

  • DrugPlacebo

    Placebo gel four times daily (This study is a within-subject design i.e. active drug applied to one leg and placebo to the other leg at the same time. Therefore the study design is not a cross-over).

06

What researchers measure

Primary outcomes

  1. Sum of Pain Intensity Differences Over 24 Hours After Initiating Treatment (SPID 24), Derived From POW.

    The primary efficacy outcome was the time-weighted SPID 24 (POW). Sum of pain intensity differences over 24 hours after initiating treatment (SPID 24) for the modified ITT population. SPID 24 derived from Pain on Walking (POW) scores assessed over 24 hours on a 0 (No pain) - 10 (Pain as bad as you can imagine) Numerical Rating Scale. SPID 24 was computed using the trapezoidal rule, i.e. Σ \[T(i) - T(i-1)\] x \[((PID)(i-1) + PID(i))/2\] in an obvious notation, where T(i) is nominal time and PID(i), the pain intensity difference at Time i, is the baseline pain intensity (PI) score - PI score at Time i.

    Time frame: 24 hours

Secondary outcomes

  1. Sum of Pain Intensity Differences Over 48 Hours After Initiating Treatment (SPID 48), Derived From POW.

    Sum of pain intensity differences over 48 hours after initiating treatment (SPID 48) (POW) was a secondary outcome. Sum of pain intensity differences over 48 hours after initiating treatment (SPID 48) for the modified ITT population. SPID 48 derived from Pain on Walking (POW) scores assessed over 48 hours on a 0 (No pain) - 10 (Pain as bad as you can imagine) Numerical Rating Scale. SPID 48 was computed using the trapezoidal rule, i.e. Σ \[T(i) - T(i-1)\] x \[((PID)(i-1) + PID(i))/2\] in an obvious notation, where T(i) is nominal time and PID(i), the pain intensity difference at Time i, is the baseline pain intensity (PI) score - PI score at Time i.

    Time frame: 48 hours

07

Results

Posted Apr 5, 2016

Participant flow

Study Start 7 Oct 2014 and End 24 dec 2014

Participant flow — Overall Study
MilestoneDiclofenac Sodium Gel 1% and Placebo Gel
Started102
Completed98
Not completed4
Withdrew: Withdrawal by subject2
Withdrew: Unable or unwilling to cooperate with st1
Withdrew: Lost to follow-up1

Outcome measures

PrimarySum of Pain Intensity Differences Over 24 Hours After Initiating Treatment (SPID 24), Derived From POW.

The primary efficacy outcome was the time-weighted SPID 24 (POW). Sum of pain intensity differences over 24 hours after initiating treatment (SPID 24) for the modified ITT population. SPID 24 derived from Pain on Walking (POW) scores assessed over 24 hours on a 0 (No pain) - 10 (Pain as bad as you can imagine) Numerical Rating Scale. SPID 24 was computed using the trapezoidal rule, i.e. Σ \[T(i) - T(i-1)\] x \[((PID)(i-1) + PID(i))/2\] in an obvious notation, where T(i) is nominal time and PID(i), the pain intensity difference at Time i, is the baseline pain intensity (PI) score - PI score at Time i.

Time frame:
24 hours
Reported as:
Mean · units on a scale (NRS)
Sum of Pain Intensity Differences Over 24 Hours After Initiating Treatment (SPID 24), Derived From POW.
units on a scale (NRS)Diclofenac Sodium Gel 1%Placebo
Sum of Pain Intensity Differences Over 24 Hours After Initiating Treatment (SPID 24), Derived From POW.50.15 ± 35.9554.83 ± 37.04
SecondarySum of Pain Intensity Differences Over 48 Hours After Initiating Treatment (SPID 48), Derived From POW.

Sum of pain intensity differences over 48 hours after initiating treatment (SPID 48) (POW) was a secondary outcome. Sum of pain intensity differences over 48 hours after initiating treatment (SPID 48) for the modified ITT population. SPID 48 derived from Pain on Walking (POW) scores assessed over 48 hours on a 0 (No pain) - 10 (Pain as bad as you can imagine) Numerical Rating Scale. SPID 48 was computed using the trapezoidal rule, i.e. Σ \[T(i) - T(i-1)\] x \[((PID)(i-1) + PID(i))/2\] in an obvious notation, where T(i) is nominal time and PID(i), the pain intensity difference at Time i, is the baseline pain intensity (PI) score - PI score at Time i.

Time frame:
48 hours
Reported as:
Mean · units on a scale (NRS)
Sum of Pain Intensity Differences Over 48 Hours After Initiating Treatment (SPID 48), Derived From POW.
units on a scale (NRS)Diclofenac Sodium Gel 1%Placebo
Sum of Pain Intensity Differences Over 48 Hours After Initiating Treatment (SPID 48), Derived From POW.151.8 ± 81.9160.84 ± 83.15

Adverse events

Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Diclofenac Sodium Gel 1%—0/102 (0%)0/102 (0%)

Baseline characteristics

ITT population: All randomized subjects who received at least one dose of the study drug on both legs = 102 Modified ITT population: Excludes the first 16 subjects who were systematically underdosed =86 Safety population: All randomized subjects who received at least one dose of study drug on either leg =102

Age, Continuous
Age, Continuous(years)Diclofenac Sodium Gel 1%
Mean27.5 ± 4.5
Sex: Female, Male
Sex: Female, Male(Participants)Diclofenac Sodium Gel 1%
Female37
Male49
Region of Enrollment
Region of Enrollment(participants)Diclofenac Sodium Gel 1%
United States86
08

Study locations

1 site
  • Lotus Clinical Research, 100 W California Blvd,
    Pasadena,, California 91105, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2014, a primary completion of Dec 2014 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2016, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 20, 2014
First posted
Oct 22, 2014
Start
Oct 2014
Primary completionActual
Dec 2014
CompletionActual
Dec 2014
Results first posted
Apr 5, 2016
Last update
Apr 5, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 5, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02271854
Lead sponsor
Novartis
Responsible party
Sponsor
First posted
Oct 22, 2014
Start date
Oct 2014
Primary completion
Dec 2014
Completion
Dec 2014
Results posted
Apr 5, 2016
Last update
Apr 5, 2016

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Diclofenac Sodium Gel

Start the discussion